The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00216268
Recruitment Status : Unknown
Verified September 2005 by Indian Council of Medical Research. Recruitment status was: Recruiting
Japanese encephalitis is the single largest cause of viral encephalitis in the world today. It occurs in yearly post monsoon outbreaks in Uttar Pradesh and other parts of India and south east Asia. There is presently no antiviral drug of proven benefit for this illness and treatment is mostly supportive. The drug Ribavirin is already in the market in use for other indications. It has been found useful in West Nile encephalitis and various hemorrhagic fevers caused by related arboviruses. This is a double blind placebo of Ribavirin in Japanese encephalitis. To the best of our knowledge, this is the first such trial in the world. The study hypothesis is that children treated with ribavirin will be no different from those getting placebo in terms of mortality, length of hospital stay, days to return to consciousness and oral feeds, days to become afebrile and convulsion free and in 3 month sequelae rate.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Months to 12 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Child between 6 months and 12 years age
Acute febrile encephalopathy
Positive IgM ELISA test for Japanese encephalitis in serum
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Viral Diseases
RNA Virus Infections
Central Nervous System Infections
Molecular Mechanisms of Pharmacological Action